Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin in HCV Genotype 1 or 4 Patients Who Failed Prior DAA Therapy
NCT02647632Phase 2Completed
- Sponsor
- ANRS
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of elbasvir + grazoprevir in hepatitis C (HCV), sponsored by ANRS. Started Jan 2016; status: completed.
02
Drugs
elbasvir + grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02647632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647632.